Atomoxetine
- Generic Name
- Atomoxetine
- Brand Names
- Strattera
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO
- CAS Number
- 83015-26-3
- Unique Ingredient Identifier
- ASW034S0B8
- Background
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associat...
- Indication
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Associated Therapies
- -
The Neuroprotective Effects of Methylphenidate and Atomoxetine in Children With ADHD: A Lipidomic Study
- Conditions
- Interventions
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 105
- Registration Number
- NCT03936491
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
A Novel Pharmacological Therapy for Obstructive Sleep Apnea
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT03919955
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Orthostatic Intolerance After Bariatric Surgery
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT03808740
- Locations
- 🇺🇸
Cyndya Shibao, Nashville, Tennessee, United States
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
- Conditions
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 44
- Registration Number
- NCT03781765
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Network Connectivity and Inhibitory Control Under Atomoxetin Challenge- A Pharmacological 'Resting State' and 'Inhibiton Task' Study in Patients With ADHD
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- RWTH Aachen University
- Target Recruit Count
- 38
- Registration Number
- NCT03661788
- Locations
- 🇩🇪
University Hospital RWTH Aachen, Aachen, Germany
Bariatric Surgery and Pharmacokinetics of Atomoxetine
- Conditions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03460210
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH
- Conditions
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03350659
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
- Conditions
- Interventions
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 239
- Registration Number
- NCT03324581
- Locations
- 🇺🇸
iResearch Atlanta, Decatur, Georgia, United States
🇺🇸Premier Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States
🇺🇸Psychiatric Associates, Overland Park, Kansas, United States
Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)
- Conditions
- Interventions
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 11
- Registration Number
- NCT03091400
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Hubert Fernandez
- Target Recruit Count
- 42
- Registration Number
- NCT02879136
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.